<DOC>
	<DOCNO>NCT01281254</DOCNO>
	<brief_summary>To determine AMG 386 plus pegylated liposomal doxorubicin ( PLD ) superior placebo plus PLD measure progression-free survival ( PFS ) The hypothesis study AMG 386 plus PLD prolong PFS compare placebo plus PLD woman recurrent partially platinum sensitive resistant epithelial ovarian , primary peritoneal fallopian tube cancer .</brief_summary>
	<brief_title>AMG 386 ( Trebananib ) Ovarian Cancer ( TRINOVA-2 )</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<criteria>Histologically cytologically document invasive epithelial ovarian , primary peritoneal , fallopian tube cancer Radiographically document disease progression either follow last dose prior regimen epithelial ovarian , primary peritoneal , fallopian tube cancer Subjects must one prior platinumbased chemotherapeutic regimen management primary disease contain carboplatin , cisplatin , another organoplatinum compound . Female 18 year age old time write informed consent obtain Adequate organ hematological function Subjects receive 3 previous regimen anti cancer therapy epithelial ovarian , primary peritoneal fallopian tube cancer Subjects treat prior pegylated liposomal doxorubicin ( PLD ) anthracyclinebased mitoxantronebased chemotherapy Subjects primary platinumrefractory disease Subjects platinumfree interval ( PFI ) &gt; 12 month last platinum base therapy History central nervous system metastasis Major surgery within 28 day prior randomization still recover prior surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Primary peritoneal cancer</keyword>
	<keyword>AMG386</keyword>
	<keyword>Pegylated Liposomal Doxorubicin</keyword>
	<keyword>Recurrent epithelial ovarian cancer</keyword>
</DOC>